These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16566033)

  • 21. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
    Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
    J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.
    Zeuzem S; Pawlotsky JM; Lukasiewicz E; von Wagner M; Goulis I; Lurie Y; Gianfranco E; Vrolijk JM; Esteban JI; Hezode C; Lagging M; Negro F; Soulier A; Verheij-Hart E; Hansen B; Tal R; Ferrari C; Schalm SW; Neumann AU;
    J Hepatol; 2005 Aug; 43(2):250-7. PubMed ID: 16082736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection.
    Hoofnagle JH; Wahed AS; Brown RS; Howell CD; Belle SH;
    J Infect Dis; 2009 Apr; 199(8):1112-20. PubMed ID: 19284286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
    Romero AI; Lagging M; Westin J; Dhillon AP; Dustin LB; Pawlotsky JM; Neumann AU; Ferrari C; Missale G; Haagmans BL; Schalm SW; Zeuzem S; Negro F; Verheij-Hart E; Hellstrand K;
    J Infect Dis; 2006 Oct; 194(7):895-903. PubMed ID: 16960776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N; Giannelli G; Antonaci A; Antonaci S
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.
    Rozenberg L; Haagmans BL; Neumann AU; Chen G; McLaughlin M; Levy-Drummer RS; Masur H; Dewar RL; Ferenci P; Silva M; Viola MS; Polis MA; Kottilil S
    AIDS; 2009 Nov; 23(18):2439-50. PubMed ID: 19898214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
    Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
    J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome in partial early virologic responders to combination therapy with peginterferon and ribavirin in patients infected with hepatitis C virus genotype 1b.
    Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Hosokawa T; Arakawa T; Fujimori M
    J Med Virol; 2011 Jan; 83(1):101-7. PubMed ID: 21108345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy.
    Rutter K; Scherzer TM; Beinhardt S; Kerschner H; Stättermayer AF; Hofer H; Popow-Kraupp T; Steindl-Munda P; Ferenci P
    Antivir Ther; 2011; 16(8):1327-33. PubMed ID: 22155914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment.
    Pham TN; Lin DM; Mulrooney-Cousins PM; Churchill ND; Kowala-Piaskowska A; Mozer-Lisewska I; Machaj A; Pazgan-Simon M; Zalewska M; Simon K; King D; Reddy SB; Michalak TI
    J Med Virol; 2013 Mar; 85(3):441-8. PubMed ID: 23280583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ribavirin rather than PEG-interferon pharmacodynamics predict nonresponse to antiviral therapy in naive chronic hepatitis C patients.
    van Vlerken LG; Huisman EJ; van Soest H; Boland GJ; Drenth JP; Siersema PD; Burger DM; van Erpecum KJ
    J Viral Hepat; 2012 Jan; 19(1):39-46. PubMed ID: 21114586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection.
    Howell CD; Dowling TC; Paul M; Wahed AS; Terrault NA; Taylor M; Jeffers L; Hoofnagle JH;
    Clin Gastroenterol Hepatol; 2008 May; 6(5):575-83. PubMed ID: 18407798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients.
    Diago M; Crespo J; Olveira A; Pérez R; Bárcena R; Sánchez-Tapias JM; Muñoz-Sánchez M; Romero-Gómez M
    Aliment Pharmacol Ther; 2007 Oct; 26(8):1131-8. PubMed ID: 17894655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan.
    Hsu CS; Liu CJ; Lai MY; Chen PJ; Kao JH; Chen DS
    Intervirology; 2007; 50(4):310-5. PubMed ID: 17622791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
    Poo JL; Sánchez-Avila F; Kershenobich D; García-Samper X; Gongora J; Uribe M
    J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S79-81. PubMed ID: 15546256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.
    Lindsay KL; Morishima C; Wright EC; Dienstag JL; Shiffman ML; Everson GT; Lok AS; Bonkovsky HL; Lee WM; Morgan TR; Ghany MG;
    Clin Gastroenterol Hepatol; 2008 Feb; 6(2):234-41. PubMed ID: 18237873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C virus therapy to date.
    Foster G; Mathurin P
    Antivir Ther; 2008; 13 Suppl 1():3-8. PubMed ID: 18432157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.